Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	41.5	39.82	36.02	29.52	99.6
Short-Term Investments	77.08	139.66	91.44	98.23	-
Cash & Short-Term Investments	118.58	179.48	127.46	127.75	99.6
Cash Growth	-33.93%	40.81%	-0.23%	28.26%	6192.04%
Other Current Assets	1.86	2.15	2.23	4.34	0.81
Total Current Assets	120.45	181.63	129.69	132.1	100.41
Net Property, Plant & Equipment	7.42	8.03	7.91	6.86	5.79
Long-Term Investments	-	5.09	-	41.88	-
Other Long-Term Assets	1.86	1.85	0.67	0.39	0.39
Total Assets	129.72	196.59	138.27	181.23	106.59
Accounts Payable	2.28	0.76	5.05	0.9	0.96
Accrued Expenses	12.22	15.4	7.38	4.89	1.29
Current Portion of Leases	1.17	1.06	0.88	0.73	0.66
Total Current Liabilities	15.66	17.21	13.3	6.52	2.91
Long-Term Leases	1.54	2.59	3.77	4.24	4.96
Total Long-Term Liabilities	1.54	2.59	3.77	4.24	4.96
Total Liabilities	17.2	19.8	17.07	10.75	7.88
Common Stock	0.03	0.03	0.02	0.02	0
Additional Paid-in Capital	387.26	373.28	237.68	226.58	1.05
Accumulated Other Comprehensive Income	0.11	0.45	-0.08	-0.1	-
Retained Earnings	-274.88	-196.98	-116.42	-56.03	-24.87
Total Common Shareholders' Equity	112.52	176.79	121.2	170.48	-23.81
Minority Interest	-	-	-	-	122.52
Shareholders' Equity	112.52	176.79	121.2	170.48	98.71
Total Liabilities & Equity	129.72	196.59	138.27	181.23	106.59
Total Debt	2.71	3.65	4.64	4.96	5.63
Net Cash (Debt)	115.87	175.84	122.81	122.79	93.98
Net Cash Growth	-34.10%	43.17%	0.02%	30.66%	5836.51%
Net Cash Per Share	3.01	5.20	5.56	29.79	53.90
Book Value	112.52	176.79	121.2	170.48	-23.81
Book Value Per Share	2.92	5.23	5.49	41.36	-13.66
Tangible Book Value	112.52	176.79	121.2	170.48	-23.81
Tangible Book Value Per Share	2.92	5.23	5.49	41.36	-13.66

Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q